赫格雷（大连）制药有限公司于2008年12月18日在长兴岛临港工业区正式成立。注册资金1亿元，总建筑面积20万平方米。

公司建成后员工可达1000多名，其中研发人员200多名。项目全部投产后预计年销售收入10.3亿元，年平均缴纳税款1.2亿元。公司现有产品45个，在研项目30余项，具有独立知识产权的产品4个，申报专利5项，创新药物2个。部分产品分别通过美国FDA和欧盟cGMP认证后进行出口。

赫格雷（大连）制药有限公司不断引入创新机制并和国内外多家著名科研机构联合研制新产品，吸纳国内外著名专家学者，以强大的技术为后盾，立足产业的高端，着眼国际市场，力求将公司铸就成为对社会负责任的世界知名制药企业。

HEGLN (Dalian) Pharmaceutical Co., Ltd. was established in Dalian Changxing Island Industrial Zone on December 18th 2008, with a registered capital of 100 million yuan. The company covers an area of 200,000 square meters. There are over 1,000 employees, with more than 200 R&D staffs. The company's annual sales revenue is expected to be 1.03 billion yuan after going into production and average annual taxes paid 120 million yuan. The company has forty-five existing products, and over thirty are under research. What's more, four products are copy-righted with five patents, and there are two innovative drugs. Partial products will be exported after getting certificates from FDA and EU.

HEGLN continues to lead in innovative